Results 141 to 150 of about 5,352 (210)

Care of HIV Patients in Long-Term Care Facilities: A Growing Concern and a Call to Action. [PDF]

Arch Clin Med Case Rep
Liu M, King WD, Butler D, Liu MH.
europepmc   +1 more source

Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report. [PDF]

Open Forum Infect Dis
Sunagawa SW, Bares SH, Scarsi KK, Podany A, Mykris T, Weinhold J, O'Neill J, Kubat M, Cramer D, Davis JM, Havens JP.   +10 more
europepmc   +1 more source

Suspected Lamotrigine-Associated Haematological Adverse Reaction in the Context of Polypharmacy, Alcohol Use, HIV, and Recent Medication Changes. [PDF]

Cureus
Alabi T, Kumar A.
europepmc   +1 more source

Giant condyloma acuminatum in a patient with HIV infection: a case report. [PDF]

AIDS Res Ther
Wang C, Wang T, Gao L, Zhang Y, Liu Y, Jia G, Zhao Z, Li J, Kang W.   +8 more
europepmc   +1 more source

To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV? [PDF]

Curr HIV/AIDS Rep
Debroy P, Lake JE.
europepmc   +1 more source

Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection

Clinical Therapeutics, 2015
PURPOSE: This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy and tolerability, drug interactions, and dosing and administration of cobicistat.
Nathan R Unger, Elizabeth M Sherman
exaly   +2 more sources

Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial [PDF]

Lung Cancer, 2022
Introduction: Exposure to osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treatment of non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation, can be substantially below average.
Anne-Marie Dingemans, Lizza Hendriks, Ard van Veelen   +2 more
exaly   +3 more sources